Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC 12-02)

X
Trial Profile

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC 12-02)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rhenium (186Re) obisbemeda (Primary)
  • Indications Astrocytoma; Diffuse intrinsic pontine glioma; Ependymoma; Glioblastoma; Glioma
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms ReSPECT; ReSPECT-GBM; ReSPECT-TM
  • Sponsors Plus Therapeutics
  • Most Recent Events

    • 15 May 2024 According to a Plus Therapeutics media release, company will present update for the Phase 2 ReSPECT-GBM trial for recurrent adult glioblastoma at one of the key neurosurgery or neuro-oncology meetings in late 2024.
    • 15 May 2024 According to a Plus Therapeutics media release, phase 2 trial update from this trial of Rhenium (186Re) obisbemeda (186RNL) in recurrent glioblastoma (rGBM) via convection enhanced delivery (Cm) presented at 2024 NMN (Nuclear Medicine and Neuro-oncology) Symposium (April 26-27).
    • 15 May 2024 According to a Plus Therapeutics media release, update report of this ReSPECT-GBM phase 1/2 dose escalation trial of rhenium (186Re) obisbemeda (Rhenium-186 Nanoliposome, 186RNL) in recurrent glioma via convection enhanced delivery (CED), presented at 2024 NMN (Nuclear Medicine and Neuro-oncology) Symposium (April 26-27).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top